

VENLAFAXINE HYDROCHLORIDE- venlafaxine hydrochloride capsule, extended release

Teva Pharmaceuticals USA, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES.

VENLAFAXINE HYDROCHLORIDE extended-release capsules, for oral use
Initial U.S. Approval: 1997

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

See full prescribing information for complete boxed warning.

- Increased risk of suicidal thoughts and behavior in pediatric patients and young adults taking antidepressants. Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors (5.1).
- Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients (8.4).

RECENT MAJOR CHANGES

Boxed Warning	8/2022
Dosage and Administration (2.10)	11/2021
Dosage and Administration (2.2, 2.3, 2.6, 2.8, 2.9, 2.11)	8/2022
Warnings and Precautions (5.7)	11/2021
Warnings and Precautions (5.1, 5.2, 5.4, 5.5, 5.6, 5.7, 5.8)	8/2022

INDICATIONS AND USAGE

Venlafaxine hydrochloride extended-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of adults with:

- Major Depressive Disorder (MDD) (1)
- Generalized Anxiety Disorder (GAD) (1)
- Social Anxiety Disorder (SAD) (1)
- Panic Disorder (PD) (1)

DOSAGE AND ADMINISTRATION

Indication	Starting Dose	Target Dose	Maximum Dose
MDD (2.2)	37.5 to 75 mg/day	75 mg/day	225 mg/day
GAD (2.3)	37.5 to 75 mg/day	75 mg/day	225 mg/day
SAD (2.4)	75 mg/day	75 mg/day	75 mg/day
PD (2.5)	37.5 mg/day	75 mg/day	225 mg/day

- Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve (2.1).
- When discontinuing treatment, reduce the dose gradually (2.10, 5.7).
- Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment (2.9).
- Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% (2.8).

DOSAGE FORMS AND STRENGTHS

- Extended-release capsules: 37.5 mg, 75 mg, and 150 mg (3).

CONTRAINDICATIONS

- Hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate, or any excipients in the venlafaxine hydrochloride extended-release capsules formulation (4).
- Concomitant use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI (4, 5.2, 7.1).

WARNINGS AND PRECAUTIONS

- **Serotonin Syndrome:** Increased risk when co-administered with other serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also when taken alone. If it occurs, discontinue venlafaxine hydrochloride extended-release capsules and initiate supportive treatment (4, 5.2, 7.1).
- **Elevated Blood Pressure:** Control hypertension before initiating treatment. Monitor blood pressure regularly during treatment (5.3).
- **Increased Risk of Bleeding:** Concomitant use of aspirin, NSAIDs, other antiplatelet drugs, warfarin, and other anticoagulants may increase risk (5.4).
- **Angle-Closure Glaucoma:** Angle-closure glaucoma has occurred in patients with untreated anatomically narrow angles, treated with antidepressants (5.5).
- **Activation of Mania or Hypomania:** Screen patients for bipolar disorder (5.6).
- **Discontinuation Syndrome:** Taper dose and monitor for discontinuation symptoms (5.7).
- **Seizures:** Can occur. Use cautiously in patients with seizure disorder (5.8).
- **Hyponatremia:** Can occur in association with SIADH (5.9).
- **Interstitial Lung Disease and Eosinophilic Pneumonia:** Can occur (5.12).
- **Sexual Dysfunction:** venlafaxine hydrochloride extended-release capsules may cause symptoms of

sexual dysfunction (5.13).

ADVERSE REACTIONS

Most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo): nausea, somnolence, dry mouth, sweating, abnormal ejaculation, anorexia, constipation, impotence (men), and libido decreased (6.1).

To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS

Pregnancy: Third trimester use may increase risk for symptoms of poor neonatal adaptation (respiratory distress, temperature instability, feeding difficulty, hypotonia, tremor, irritability) in the neonate (8.1).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 9/2022

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 General Administration Information
- 2.2 Major Depressive Disorder
- 2.3 Generalized Anxiety Disorder
- 2.4 Social Anxiety Disorder (Social Phobia)
- 2.5 Panic Disorder
- 2.6 Screen for Bipolar Disorder Prior to Starting Venlafaxine Hydrochloride Extended-Release Capsules
- 2.7 Switching Patients from Venlafaxine Tablets
- 2.8 Dosage Recommendations for Patients with Hepatic Impairment
- 2.9 Dosage Recommendations for Patients with Renal Impairment
- 2.10 Discontinuing Treatment with Venlafaxine Hydrochloride Extended-Release Capsules
- 2.11 Switching Patients to or from a Monoamine Oxidase Inhibitor (MAOI) Antidepressant

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults
- 5.2 Serotonin Syndrome
- 5.3 Elevated Blood Pressure
- 5.4 Increased Risk of Bleeding
- 5.5 Angle-Closure Glaucoma
- 5.6 Activation of Mania or Hypomania
- 5.7 Discontinuation Syndrome
- 5.8 Seizures
- 5.9 Hyponatremia
- 5.10 Weight and Height Changes in Pediatric Patients
- 5.11 Appetite Changes in Pediatric Patients
- 5.12 Interstitial Lung Disease and Eosinophilic Pneumonia
- 5.13 Sexual Dysfunction

6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Drugs Having Clinically Important Interactions with Venlafaxine Hydrochloride Extended-Release Capsules
- 7.2 Other Drug Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment
- 8.7 Renal Impairment

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Major Depressive Disorder
- 14.2 Generalized Anxiety Disorder
- 14.3 Social Anxiety Disorder (also known as Social Phobia)
- 14.4 Panic Disorder

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)].

Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients [see Use in Specific Populations (8.4)].

1 INDICATIONS AND USAGE

Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:

- Major Depressive Disorder (MDD) [see Clinical Studies (14.1)]
- Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2)]
- Social Anxiety Disorder (SAD) [see Clinical Studies (14.3)]
- Panic Disorder (PD) [see Clinical Studies (14.4)]

2 DOSAGE AND ADMINISTRATION

2.1 General Administration Information

Administer venlafaxine hydrochloride extended-release capsules as a single dose with food, either in the morning or in the evening at approximately the same time each day [see Clinical Pharmacology (12.3)]. Swallow capsules whole with fluid. Do not divide, crush, chew, or place in water.

The capsule may also be administered by carefully opening the capsule and sprinkling the entire contents on a spoonful of applesauce. This drug/food mixture should be swallowed immediately without chewing and followed with a glass of water to ensure complete swallowing of the pellets (spheroids).

2.2 Major Depressive Disorder

For most patients, the recommended starting dose for venlafaxine hydrochloride extended-release capsules is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 4 days. In the clinical studies establishing efficacy, upward titration was permitted at intervals of 2 weeks or more.

2.3 Generalized Anxiety Disorder

For most patients, the recommended starting dose for venlafaxine hydrochloride extended-release capsules is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new

patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 4 days.

2.4 Social Anxiety Disorder (Social Phobia)

The recommended dose is 75 mg per day, administered in a single dose. There was no evidence that higher doses confer any additional benefit.

2.5 Panic Disorder

The recommended starting dose is 37.5 mg per day of venlafaxine hydrochloride extended-release capsules for 7 days. Patients not responding to 75 mg per day may benefit from dose increases to a maximum of approximately 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 7 days.

2.6 Screen for Bipolar Disorder Prior to Starting Venlafaxine Hydrochloride Extended-Release Capsules

Prior to initiating treatment with venlafaxine hydrochloride extended-release capsules, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see *Warnings and Precautions* (5.6)].

2.7 Switching Patients from Venlafaxine Tablets

Patients with depression who are currently being treated with venlafaxine tablets (immediate release) may be switched to venlafaxine hydrochloride extended-release capsules at the nearest equivalent dose (mg per day), e.g., 37.5 mg venlafaxine twice a day to 75 mg venlafaxine hydrochloride extended-release capsules once daily. However, individual dosage adjustments may be necessary.

2.8 Dosage Recommendations for Patients with Hepatic Impairment

Reduce the venlafaxine hydrochloride extended-release capsules total daily dose by 50% in patients with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. Reduce the total daily dose by 50% or more in patients with severe hepatic impairment (Child-Pugh Class C) or hepatic cirrhosis [see *Use in Specific Populations* (8.6)].

2.9 Dosage Recommendations for Patients with Renal Impairment

Reduce the venlafaxine hydrochloride extended-release capsules total daily dose by 25% to 50% in patients with mild (CLcr 60 to 89 mL/min) or moderate (CLcr 30 to 59 mL/min) renal impairment. Reduce the total daily dose by 50% or more in patients undergoing hemodialysis or with severe renal impairment (CLcr < 30 mL/min). Because there was much individual variability in clearance between patients with renal impairment, individualization of dosage is recommended in some patients [see *Use in Specific Populations* (8.7)].

2.10 Discontinuing Treatment with Venlafaxine Hydrochloride Extended-Release Capsules

A gradual reduction in the dose, rather than abrupt cessation, is recommended when discontinuing therapy with venlafaxine hydrochloride extended-release capsules. In clinical studies with venlafaxine hydrochloride extended-release capsules, tapering was achieved by reducing the daily dose by 75 mg at one-week intervals. Individualization of tapering may be necessary. In some patients, discontinuation may need to occur over a period of several months [see *Warnings and Precautions* (5.7)].

2.11 Switching Patients to or from a Monoamine Oxidase Inhibitor (MAOI) Antidepressant

At least 14 days must elapse between discontinuation of an MAOI antidepressant and initiation of venlafaxine hydrochloride extended-release capsules. In addition, at least 7 days must elapse after stopping venlafaxine hydrochloride extended-release capsules before starting an MAOI antidepressant [see *Contraindications* (4), *Warnings and Precautions* (5.2), and *Drug Interactions* (7.1)].

3 DOSAGE FORMS AND STRENGTHS

Venlafaxine hydrochloride extended-release capsules, USP are available in the following strengths:

- 37.5 mg extended-release capsules - light-gray opaque cap and buff opaque body with “93” and “7384” on both body and cap.
- 75 mg extended-release capsules - buff opaque cap and buff opaque body with “93” and “7385” on both body and cap.
- 150 mg extended-release capsules - light-orange opaque cap and light-orange opaque body with “93” and “7386” on both body and cap.

4 CONTRAINDICATIONS

- Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:
- with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation [see *Adverse Reactions* (6.2)].
 - taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome [see *Dosage and Administration* (2.11), *Warnings and Precautions* (5.2), and *Drug Interactions* (7.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1.

Table 1: Risk Differences of the Number of Patients of Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric* and Adult Patients

Age Range	Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated
	Increases Compared to Placebo
< 18 years old	14 additional patients
18 to 24 years old	5 additional patients
	Decreases Compared to Placebo
25 to 64 years old	1 fewer patient
≥ 65 years old	6 fewer patients

*Venlafaxine hydrochloride extended-release capsules are not approved in pediatric patients.

It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.

Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing venlafaxine hydrochloride extended-release capsules, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

5.2 Serotonin Syndrome

Serotonin-norepinephrine reuptake inhibitors (SNRIs), including venlafaxine hydrochloride extended-release capsules can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see *Contraindications (4)*, *Drug Interactions (7.1)*]. Serotonin syndrome can also occur when these drugs are used alone.

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of venlafaxine hydrochloride extended-release capsules with MAOIs is contraindicated. In addition, do not initiate venlafaxine hydrochloride extended-release capsules in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking venlafaxine hydrochloride extended-release capsules, discontinue venlafaxine hydrochloride extended-release capsules before initiating treatment with the MAOI [see *Contraindications (4)*, *Drug Interactions (7.1)*].

Monitor all patients taking venlafaxine hydrochloride extended-release capsules for the emergence of serotonin syndrome. Discontinue treatment with venlafaxine hydrochloride extended-release capsules and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

5.3 Elevated Blood Pressure

In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension [see *Adverse Reactions (6.1)*].

Monitor blood pressure before initiating treatment with venlafaxine hydrochloride extended-release capsules and regularly during treatment. Control pre-existing hypertension before initiating treatment with venlafaxine hydrochloride extended-release capsules. Use caution in treating patients with pre-existing hypertension or cardiovascular or cerebrovascular conditions that might be compromised by increases in blood pressure. Sustained blood pressure elevation can lead to adverse outcomes. Cases of elevated blood pressure requiring immediate treatment have been reported with venlafaxine hydrochloride extended-release capsules. Consider dose reduction or discontinuation of treatment for patients who experience a sustained increase in blood pressure.

Across all clinical studies with venlafaxine tablets, 1.4% of patients in the venlafaxine hydrochloride extended-release capsule treated groups experienced a ≥ 15 mm Hg increase in supine diastolic blood pressure (SDBP)

≥ 105 mm Hg, compared to 0.9% of patients in the placebo groups. Similarly, 1% of patients in the venlafaxine hydrochloride extended-release capsule treated groups experienced a ≥ 20 mm Hg increase in supine systolic blood pressure (SSBP) with blood pressure ≥ 180 mm Hg, compared to 0.3% of patients in the placebo groups [see *Adverse Reactions (6.1)*]. Treatment with venlafaxine hydrochloride extended-release capsules was associated with sustained hypertension (defined as SDBP ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for three consecutive on-therapy visits [see *Adverse Reactions (6.1)*]. An insufficient number of patients received mean doses of venlafaxine hydrochloride extended-release capsules over 300 mg per day in clinical studies to fully evaluate the incidence of sustained increases in blood pressure at these higher doses.

5.4 Increased Risk of Bleeding

Drugs that interfere with serotonin reuptake inhibition, including venlafaxine hydrochloride extended-release capsules, may increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and gastrointestinal hemorrhage to life-threatening hemorrhage. Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anti-coagulants or other drugs known to affect platelet function may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of

gastrointestinal bleeding.

Inform patients about the risk of bleeding associated with the concomitant use of venlafaxine hydrochloride extended-release capsules nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing venlafaxine hydrochloride extended-release capsules.

5.5 Angle-Closure Glaucoma

The pupillary dilation that occurs following use of many antidepressant drugs including venlafaxine hydrochloride extended-release capsules may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including venlafaxine hydrochloride extended-release capsules, in patients with untreated anatomically narrow angles.

5.6 Activation of Mania or Hypomania

In patients with bipolar disorder, treating a depressive episode with venlafaxine hydrochloride extended-release capsules or another antidepressant may precipitate a mixed/manic episode. Mania or hypomania was reported in venlafaxine hydrochloride extended-release capsule treated patients in the premarketing studies in MDD, SAD, and PD (see Table 2). Prior to initiating treatment with venlafaxine hydrochloride extended-release capsules, screen for any personal or family history of bipolar disorder, mania, or hypomania.

Table 2: Incidence (%) of Mania or Hypomania Reported in Venlafaxine Hydrochloride Extended-Release Capsule Treated Patients in the Premarketing Studies

Indication	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
MDD	0.3	0.0
GAD	0.0	0.2
SAD	0.2	0.0
PD	0.1	0.0

5.7 Discontinuation Syndrome

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, including prospective analyses of clinical studies in GAD and retrospective surveys of studies in MDD and SAD. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

There have been postmarketing reports of serious discontinuation symptoms which can be protracted and severe. Completed suicide, suicidal thoughts, aggression and violent behavior have been observed in patients during reduction in venlafaxine hydrochloride extended-release capsules dosage, including during discontinuation. Other postmarketing reports describe visual changes (such as blurred vision or trouble focusing) and increased blood pressure after stopping or reducing the dose of venlafaxine hydrochloride extended-release capsules.

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs, and SSRIs, there have been reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: irritability, lethargy, emotional lability, tinnitus, and seizures.

Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine hydrochloride extended-release capsules. A gradual reduction in the dose, rather than abrupt cessation, is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over a period of several months [see Dosage and

5.8 Seizures

Cases of seizure have been reported with venlafaxine therapy. Venlafaxine hydrochloride extended-release capsules has not been systematically evaluated in patients with seizure disorder. Venlafaxine hydrochloride extended-release capsules should be prescribed with caution in patients with a seizure disorder.

5.9 Hyponatremia

Hyponatremia can occur as a result of treatment with SNRIs, including venlafaxine hydrochloride extended-release capsules. In many cases, the hyponatremia appears to be the result of the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SNRIs. Also, patients taking diuretics, or those who are otherwise volume-depleted, may be at greater risk [see *Use in Specific Populations* (8.5) and *Clinical Pharmacology* (12.3)]. Consider discontinuation of venlafaxine hydrochloride extended-release capsules in patients with symptomatic hyponatremia, and institute appropriate medical intervention.

Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.

5.10 Weight and Height Changes in Pediatric Patients

Weight Changes

The average change in body weight and incidence of weight loss (percentage of patients who lost 3.5% or more) in the placebo-controlled pediatric studies in MDD, GAD, and SAD are shown in Tables 3 and 4.

Table 3: Average Change in Body Weight (kg) From Beginning of Treatment in Pediatric Patients^a in Double-blind, Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
MDD and GAD (4 pooled studies, 8 weeks)	-0.45 (n = 333)	+0.77 (n = 333)
SAD (16 weeks)	-0.75 (n = 137)	+0.76 (n = 148)

^a Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.

Table 4: Incidence (%) of Pediatric Patients

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
MDD and GAD (4 pooled studies, 8 weeks)	18 ^b (n = 333)	3.6 (n = 333)
SAD (16 weeks)	47 ^b (n = 137)	14 (n = 148)

^a Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.

^b p < 0.001 versus placebo

Weight loss was not limited to patients with anorexia [see *Warnings and Precautions* (5.11)].

The risks associated with longer term venlafaxine hydrochloride extended-release capsule use were assessed in an open-label MDD study of children and adolescents who received venlafaxine hydrochloride extended-release capsules for up to six months. The children and adolescents in the study had increases in weight that were less than expected, based on data from age- and sex-matched peers. The difference between observed weight gain and expected weight gain was larger for children (< 12 years old) than for adolescents (≥ 12 years old).

Venlafaxine hydrochloride extended-release capsules are not approved for use in

pediatric patients [Use in Specific Populations (8.4)].

Height Changes

Table 5 shows the average height increase in pediatric patients in the short-term, placebo-controlled MDD, GAD, and SAD studies. The differences in height increases in GAD and MDD studies were most notable in patients younger than 12 years old.

Table 5: Average Height Increases (cm) in Pediatric Patients

Indication (Duration)	Venlafaxine Hydrochloride Extended- Release Capsules	Placebo
MDD (8 weeks)	0.8 (n = 146)	0.7 (n = 147)
GAD (8 weeks)	0.3 ^b (n = 122)	1.0 (n = 132)
SAD (16 weeks)	1.0 (n = 109)	1.0 (n = 112)

^a Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.
^b p = 0.041

In the six-month, open-label MDD study, children and adolescents had height increases that were less than expected, based on data from age- and sex-matched peers. The difference between observed and expected growth rates was larger for children (< 12 years old) than for adolescents (≥ 12 years old) [see Use in Specific Populations (8.4)].

5.11 Appetite Changes in Pediatric Patients

Decreased appetite (reported as anorexia) was more commonly observed in venlafaxine hydrochloride extended-release capsule treated patients versus placebo-treated patients in the premarketing evaluation of venlafaxine hydrochloride extended-release capsules for MDD, GAD, and SAD (see Table 6).

Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients [see Use in Specific Populations (8.4)].

Table 6: Incidence (%) of Decreased Appetite and Associated Discontinuation Rates^a (%) in Pediatric Patients^b in Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules Incidence	Discontinuation	Placebo Incidence	Discontinuation
MDD and GAD (pooled, 8 weeks)	10	0.0	3	-
SAD (16 weeks)	22	0.7	3	0.0

^a The discontinuation rates for weight loss were 0.7% for patients receiving either venlafaxine hydrochloride extended-release capsules or placebo.

^b Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.

5.12 Interstitial Lung Disease and Eosinophilic Pneumonia

Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine therapy have been rarely reported. The possibility of these events should be considered in venlafaxine hydrochloride extended-release capsules-treated patients who present with progressive dyspnea, cough or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of venlafaxine hydrochloride extended-release capsules should be considered.

5.13 Sexual Dysfunction

Use of SNRIs, including venlafaxine hydrochloride extended-release capsules, may cause symptoms of sexual dysfunction [see *Adverse Reactions* (6.1)]. In male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SNRI use may result in decreased libido and delayed or absent orgasm.

It is important for prescribers to inquire about sexual function prior to initiation of venlafaxine hydrochloride extended-release capsules and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Hypersensitivity [see *Contraindications* (4)]
- Suicidal Thoughts and Behaviors in Adolescents and Young Adults [see *Warnings and Precautions* (5.1)]
- Serotonin Syndrome [see *Warnings and Precautions* (5.2)]
- Elevated Blood Pressure [see *Warnings and Precautions* (5.3)]
- Increased Risk of Bleeding [see *Warnings and Precautions* (5.4)]
- Angle Closure Glaucoma [see *Warnings and Precautions* (5.5)]
- Activation of Mania/Hypomania [see *Warnings and Precautions* (5.6)]
- Discontinuation Syndrome [see *Warnings and Precautions* (5.7)]
- Seizure [see *Warnings and Precautions* (5.8)]
- Hyponatremia [see *Warnings and Precautions* (5.9)]
- Weight and Height changes in Pediatric Patients [see *Warnings and Precautions* (5.10)]
- Appetite Changes in Pediatric Patients [see *Warnings and Precautions* (5.11)]
- Interstitial Lung Disease and Eosinophilic Pneumonia [see *Warnings and Precautions* (5.12)]
- Sexual Dysfunction [see *Warnings and Precautions* (5.13)]

6.1 Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.

Most Common Adverse Reactions

The most commonly observed adverse reactions in the clinical study database in venlafaxine hydrochloride extended-release capsule treated patients in MDD, GAD, SAD, and PD (incidence $\geq 5\%$ and at least twice the rate of placebo) were: nausea (30.0%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).

Adverse Reactions Reported as Reasons for Discontinuation of Treatment

Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received venlafaxine hydrochloride extended-release capsules (37.5 mg to 225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.

The most common adverse reactions leading to discontinuation in $\geq 1\%$ of the venlafaxine hydrochloride extended-release capsule treated patients in the short-term studies (up to 12 weeks) across indications are shown in Table 7.

Table 7: Incidence (%) of Patients Reporting Adverse Reactions Leading to Discontinuation in Placebo-controlled Clinical Studies (up to 12 Weeks Duration)

Body System Adverse Reaction	Venlafaxine Hydrochloride Extended-Release Capsules n = 3,558	Placebo n = 2,197
---------------------------------	---	----------------------

Body as a whole		
Asthenia	1.7	0.5
Headache	1.5	0.8
Digestive system		
Nausea	4.3	0.4
Nervous system		
Dizziness	2.2	0.8
Insomnia	2.1	0.6
Somnolence	1.7	0.3
Skin and appendages	1.5	0.6
Sweating	1.0	0.2

Common Adverse Reactions in Placebo-controlled Studies

The number of patients receiving multiple doses of venlafaxine hydrochloride extended-release capsules during the premarketing assessment for each approved indication is shown in Table 8. The conditions and duration of exposure to venlafaxine in all development programs varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient (venlafaxine tablets only) and outpatient studies, fixed-dose, and titration studies.

Table 8: Patients Receiving Venlafaxine Hydrochloride Extended-Release Capsules in Premarketing Clinical Studies

Indication	Venlafaxine Hydrochloride Extended-Release Capsules
MDD	705 ^a
GAD	1,381
SAD	819
PD	1,314

^a In addition, in the premarketing assessment of venlafaxine tablets, multiple doses were administered to 2,897 patients in studies for MDD.

The incidences of common adverse reactions (those that occurred in $\geq 2\%$ of venlafaxine hydrochloride extended-release capsule treated patients [357 MDD patients, 1,381 GAD patients, 819 SAD patients, and 1,001 PD patients] and more frequently than placebo) in venlafaxine hydrochloride extended-release capsule treated patients in short-term, placebo-controlled, fixed- and flexible-dose clinical studies (doses 37.5 mg to 225 mg per day) are shown in Table 9.

The adverse reaction profile did not differ substantially between the different patient populations.

Table 9: Common Adverse Reactions: Percentage of Patients Reporting Adverse Reactions ($\geq 2\%$ and $>$ placebo) in Placebo-controlled Studies (up to 12 Weeks Duration) across All Indications

Body System	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
Adverse Reaction	n = 3,558	n = 2,197
Body as a whole		
Asthenia	12.6	7.8
Cardiovascular system		
Hypertension	3.4	2.6
Palpitation	2.2	2.0
Vasodilatation	3.7	1.9
Digestive system		

Anorexia	9.8	2.6
Constipation	9.3	3.4
Diarrhea	7.7	7.2
Dry mouth	14.8	5.3
Nausea	30.0	11.8
Vomiting	4.3	2.7
Nervous system		
Abnormal dreams	2.9	1.4
Dizziness	15.8	9.5
Insomnia	17.8	9.5
Libido decreased	5.1	1.6
Nervousness	7.1	5.0
Paresthesia	2.4	1.4
Somnolence	15.3	7.5
Tremor	4.7	1.6
Respiratory system		
Yawn	3.7	0.2
Skin and appendages		
Sweating (including night sweats)	11.4	2.9
Special senses		
Abnormal vision	4.2	1.6
Urogenital system		
Abnormal ejaculation/orgasm (men) ^a	9.9	0.5
Anorgasmia (men) ^a	3.6	0.1
Anorgasmia (women) ^b	2.0	0.2
Impotence (men) ^a	5.3	1.0

^a Percentages based on the number of men (venlafaxine hydrochloride extended-release capsules, n = 1,440; placebo, n = 923)

^b Percentages based on the number of women (venlafaxine hydrochloride extended-release capsules, n = 2,118; placebo, n = 1,274)

Other Adverse Reactions Observed in Clinical Studies

Body as a whole – Photosensitivity reaction, chills

Cardiovascular system – Postural hypotension, syncope, hypotension, tachycardia

Digestive system – Gastrointestinal hemorrhage [see *Warnings and Precautions* (5.4)], bruxism

Hemic/Lymphatic system – Ecchymosis [see *Warnings and Precautions* (5.4)]

Metabolic/Nutritional – Hypercholesterolemia, weight gain [see *Warnings and Precautions* (5.10)], weight loss [see *Warnings and Precautions* (5.10)]

Nervous system – Seizures [see *Warnings and Precautions* (5.8)], manic reaction [see *Warnings and Precautions* (5.6)], agitation, confusion, akathisia, hallucinations, hypertonia, myoclonus, depersonalization, apathy

Skin and appendages – Urticaria, pruritus, rash, alopecia

Special senses – Mydriasis, abnormality of accommodation, tinnitus, taste perversion

Urogenital system – Urinary retention, urination impaired, urinary incontinence, urinary frequency increased, menstrual disorders associated with increased bleeding or increased irregular bleeding (e.g., menorrhagia, metrorrhagia)

Vital Sign Changes

In placebo-controlled premarketing studies, there were increases in mean blood pressure (see Table 10). Across most indications, a dose-related increase in mean

supine systolic and diastolic blood pressure was evident in patients treated with venlafaxine hydrochloride extended-release capsules. Across all clinical studies in MDD, GAD, SAD and PD, 1.4% of patients in the venlafaxine hydrochloride extended-release capsules groups experienced an increase in SDBP of ≥ 15 mm Hg along with a blood pressure ≥ 105 mm Hg, compared to 0.9% of patients in the placebo groups. Similarly, 1% of patients in the venlafaxine hydrochloride extended-release capsules groups experienced an increase in SSBP of ≥ 20 mm Hg with a blood pressure ≥ 180 mm Hg, compared to 0.3% of patients in the placebo groups.

Table 10: Final On-therapy Mean Changes From Baseline in Supine Systolic (SSBP) and Diastolic (SDBP) Blood Pressure (mm Hg) in Placebo-controlled Studies

Indication (Duration)	Venlafaxine Hydrochloride Extended-release Capsules				Placebo	
	≤ 75 mg per day		> 75 mg per day			
	SSBP	SDBP	SSBP	SDBP	SSBP	SDBP
MDD						
(8 to 12 weeks)	-0.28	0.37	2.93	3.56	-1.08	-0.10
GAD						
(8 weeks)	-0.28	0.02	2.40	1.68	-1.26	-0.92
(6 months)	1.27	-0.69	2.06	1.28	-1.29	-0.74
SAD						
(12 weeks)	-0.29	-1.26	1.18	1.34	-1.96	-1.22
(6 months)	-0.98	-0.49	2.51	1.96	-1.84	-0.65
PD						
(10 to 12 weeks)	-1.15	0.97	-0.36	0.16	-1.29	-0.99

Venlafaxine hydrochloride extended-release capsule treatment was associated with sustained hypertension (defined as Supine Diastolic Blood Pressure [SDBP] ≥ 90 mm Hg and ≥ 10 mm Hg above baseline for three consecutive on-therapy visits (see Table 11). An insufficient number of patients received mean doses of venlafaxine hydrochloride extended-release capsules over 300 mg per day in clinical studies to fully evaluate the incidence of sustained increases in blood pressure at these higher doses.

Table 11: Sustained Elevations in SDBP in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies

Indication	Dose Range (mg per day)	Incidence (%)
MDD	75 to 375 ^a	19/705 (3)
GAD	37.5 to 225	5/1011 (0.5)
SAD	75 to 225	5/771 (0.6)
PD	75 to 225	9/973 (0.9)

^a Maximum recommended dosage for venlafaxine hydrochloride extended-release capsules is 225 mg once daily.

Venlafaxine hydrochloride extended-release capsules were associated with mean increases in pulse rate compared with placebo in premarketing placebo-controlled studies (see Table 12) [see *Warnings and Precautions* (5.3, 5.4)].

Table 12: Approximate Mean Final On-therapy Increase in Pulse Rate (beats/min) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Placebo-controlled Studies (up to 12 Weeks Duration)

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
MDD (12 weeks)	2	1
GAD (8 weeks)	2	< 1

SAD (12 weeks)	3	1
PD (12 weeks)	1	< 1

Laboratory Changes

Serum Cholesterol

Venlafaxine hydrochloride extended-release capsules were associated with mean final increases in serum cholesterol concentrations compared with mean final decreases for placebo in premarketing MDD, GAD, SAD and PD clinical studies (Table 13).

Table 13: Mean Final On-therapy Changes in Cholesterol Concentrations (mg/dL) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
MDD (12 weeks)	+1.5	-7.4
GAD (8 weeks) (6 months)	+1.0 +2.3	-4.9 -7.7
SAD (12 weeks) (6 months)	+7.9 +5.6	-2.9 -4.2
PD (12 weeks)	5.8	-3.7

Venlafaxine hydrochloride extended-release capsule treatment for up to 12 weeks in premarketing placebo-controlled trials for major depressive disorder was associated with a mean final on-therapy increase in serum cholesterol concentration of approximately 1.5 mg/dL compared with a mean final decrease of 7.4 mg/dL for placebo. Venlafaxine hydrochloride extended-release capsule treatment for up to 8 weeks and up to 6 months in premarketing placebo-controlled GAD trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 1.0 mg/dL and 2.3 mg/dL, respectively while placebo subjects experienced mean final decreases of 4.9 mg/dL and 7.7 mg/dL, respectively. Venlafaxine hydrochloride extended-release capsule treatment for up to 12 weeks and up to 6 months in premarketing placebo-controlled Social Anxiety Disorder trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 7.9 mg/dL and 5.6 mg/dL, respectively, compared with mean final decreases of 2.9 mg/dL and 4.2 mg/dL, respectively, for placebo. Venlafaxine hydrochloride extended-release capsule treatment for up to 12 weeks in premarketing placebo-controlled panic disorder trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 5.8 mg/dL compared with a mean final decrease of 3.7 mg/dL for placebo.

Patients treated with venlafaxine tablets (immediate release) for at least 3 months in placebo-controlled 12-month extension trials had a mean final on-therapy increase in total cholesterol of 9.1 mg/dL compared with a decrease of 7.1 mg/dL among placebo-treated patients. This increase was duration dependent over the study period and tended to be greater with higher doses. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol \geq 50 mg/dL from baseline and to a value \geq 261 mg/dL, or 2) an average on-therapy increase in serum cholesterol \geq 50 mg/dL from baseline and to a value \geq 261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients.

Serum Triglycerides

Venlafaxine hydrochloride extended-release capsules were associated with mean final on-therapy increases in fasting serum triglycerides compared with placebo in premarketing clinical studies of SAD and PD up to 12 weeks (pooled data) and 6 months duration (Table 14).

Table 14: Mean Final On-therapy Increases in Triglyceride Concentrations (mg/dL) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies

Indication		
-------------------	--	--

Indication (Duration)	Venlafaxine Hydrochloride Extended-Release Capsules	Placebo
SAD (12 weeks)	8.2	0.4
SAD (6 months)	11.8	1.8
PD (12 weeks)	5.9	0.9
PD (6 months)	9.3	0.3

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of venlafaxine hydrochloride extended-release capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Body as a whole – Anaphylaxis, angioedema

Cardiovascular system – QT prolongation, ventricular fibrillation, ventricular tachycardia (including torsade de pointes), takotsubo cardiomyopathy

Digestive system – Pancreatitis

Hemic/Lymphatic system – Mucous membrane bleeding [see Warnings and Precautions (5.4)], blood dyscrasias (including agranulocytosis, aplastic anemia, neutropenia and pancytopenia), prolonged bleeding time, thrombocytopenia

Metabolic/Nutritional – Hyponatremia [see Warnings and Precautions (5.9)], Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion [see Warnings and Precautions (5.9)], abnormal liver function tests, hepatitis, prolactin increased

Musculoskeletal – Rhabdomyolysis

Nervous system – Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.2)], serotonergic syndrome [see Warnings and Precautions (5.2)], delirium, extrapyramidal reactions (including dystonia and dyskinesia), impaired coordination and balance, tardive dyskinesia

Respiratory system – Dyspnea, interstitial lung disease, pulmonary eosinophilia [see Warnings and Precautions (5.12)]

Skin and appendages – Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme

Special senses – Angle closure glaucoma [see Warnings and Precautions (5.5)]

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

Table 15: Clinically Important Drug Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

Monoamine Oxidase Inhibitors (MAOI)	
<i>Clinical Impact</i>	The concomitant use of SNRIs, including venlafaxine hydrochloride extended-release capsules, with MAOIs increases the risk of serotonin syndrome.
<i>Intervention</i>	Concomitant use of venlafaxine hydrochloride extended-release capsules are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Dosage and Administration (2.11), Contraindications (4) and Warnings and Precautions (5.2)]

Other Serotonergic Drugs	
<i>Clinical Impact</i>	Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs increases the risk of serotonin syndrome.
<i>Intervention</i>	Monitor for symptoms of serotonin syndrome when venlafaxine hydrochloride extended-release capsules are used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of venlafaxine hydrochloride extended-release capsules and/or concomitant serotonergic drugs [see <i>Dosage and Administration</i> (2.11) and <i>Warnings and Precautions</i> (5.2)].
Drugs that Interfere with Hemostasis	
<i>Clinical Impact</i>	Concomitant use of venlafaxine hydrochloride extended-release capsules with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of venlafaxine hydrochloride extended-release capsules on the release of serotonin by platelets.
<i>Intervention</i>	Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when venlafaxine hydrochloride extended-release capsules are initiated or discontinued [see <i>Warnings and Precautions</i> (5.4)].
Effect of CYP3A Inhibitors	
<i>Clinical Impact</i>	Concomitant use of a CYP3A inhibitor increases the C _{max} and AUC of venlafaxine and O-desmethylvenlafaxine (ODV) [see <i>Clinical Pharmacology</i> (12.3)], which may increase the risk of toxicity of venlafaxine hydrochloride extended-release capsules
<i>Intervention</i>	Consider reducing the dose of venlafaxine hydrochloride extended-release capsules.
CYP2D6 Substrates	
<i>Clinical Impact</i>	Concomitant use of venlafaxine hydrochloride extended-release capsules increases C _{max} and AUC of a CYP2D6 substrate, which may increase the risk of toxicity of the CYP2D6 substrate [see <i>Clinical Pharmacology</i> (12.3)].
<i>Intervention</i>	Consider reduction in dose of concomitant CYP2D6 substrates.

7.2 Other Drug Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

Central Nervous System (CNS)-Active Drugs

The risk of using venlafaxine concomitantly with other CNS-active drugs (including alcohol) has not been systematically evaluated. Consequently, caution is advised when venlafaxine hydrochloride extended-release capsules are taken concomitantly in combination with other CNS-active drugs.

Weight Loss Agents

Concomitant use of venlafaxine hydrochloride extended-release capsules and weight loss agents is not recommended. The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Venlafaxine hydrochloride extended-release capsules are not indicated for weight loss alone or in combination with other products.

Laboratory Test Interference

False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including venlafaxine hydrochloride extended-release capsules, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at <https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/>.

Risk Summary

Available data from published epidemiologic studies on venlafaxine use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse fetal outcomes (*see Data*). Available data from observational studies with venlafaxine have identified a potential increased risk for preeclampsia when used during mid to late pregnancy; exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage (*see Clinical Considerations*). There are risks associated with untreated depression in pregnancy and poor neonatal adaptation in newborns with exposure to SNRIs, including venlafaxine hydrochloride extended-release capsules, during pregnancy (*see Clinical Considerations*).

In animal studies, there was no evidence of malformations or fetotoxicity following administration of venlafaxine during organogenesis at doses up to 2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m² basis. Postnatal mortality and decreased pup weights were observed following venlafaxine administration to pregnant rats during gestation and lactation at 2.5 times (mg/m²) the maximum human daily dose.

The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryo/Fetal Risk

Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study that followed 201 pregnant women with a history of major depression who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

Maternal Adverse Reactions

Exposure to venlafaxine in mid to late pregnancy may increase the risk for preeclampsia, and exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage.

Fetal/Neonatal Adverse Reactions

Neonates exposed to SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding

difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying. These findings are consistent with either a direct toxic effect of SNRIs or possibly a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see *Warnings and Precautions* (5.2)]. Monitor neonates who were exposed to venlafaxine hydrochloride extended-release capsules in the third trimester of pregnancy for drug discontinuation syndrome (see *Data*).

Data

Human Data

Published epidemiological studies of pregnant women exposed to venlafaxine have not established an increased risk of major birth defects, miscarriage or other adverse developmental outcomes. Methodological limitations may both fail to identify true findings and also identify findings that are not true.

Retrospective cohort studies based on claims data have shown an association between venlafaxine use and preeclampsia, compared to depressed women who did not take an antidepressant during pregnancy. One study that assessed venlafaxine exposure in the second trimester or first half of the third trimester and preeclampsia showed an increased risk compared to unexposed depressed women (adjusted [adj] RR 1.57, 95% confidence interval [CI] 1.29 to 1.91). Preeclampsia was observed at venlafaxine doses equal to or greater than 75 mg per day and a duration of treatment >30 days. Another study that assessed venlafaxine exposure in gestational weeks 10 to 20 and preeclampsia showed an increased risk at doses equal to or greater than 150 mg per day. Available data are limited by possible outcome misclassification and possible confounding due to depression severity and other confounders.

Retrospective cohort studies based on claims data have suggested an association between venlafaxine use near the time of delivery or through delivery and postpartum hemorrhage. One study showed an increased risk for postpartum hemorrhage when venlafaxine exposure occurred through delivery, compared to unexposed depressed women (adj RR 2.24 [95% CI 1.69 to 2.97]). There was no increased risk in women who were exposed to venlafaxine earlier in pregnancy. Limitations of this study include possible confounding due to depression severity and other confounders. Another study showed an increased risk for postpartum hemorrhage when SNRI exposure occurred for at least 15 days in the last month of pregnancy or through delivery, compared to unexposed women (adj RR 1.64 to 1.76). The results of this study may be confounded by the effects of depression.

Animal Data

Venlafaxine did not cause malformations in offspring of rats or rabbits given doses up to 2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m² basis. However, in rats, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation, when dosing began during pregnancy and continued until weaning. The cause of these deaths is not known. These effects occurred at 2.5 times (mg/m²) the maximum human daily dose. The no effect dose for rat pup mortality was 0.25 times the human dose on a mg/m² basis.

When desvenlafaxine succinate, the major metabolite of venlafaxine, was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no fetal malformations were observed. These doses were associated with a plasma exposure (AUC) 19 times (rats) and 0.5 times (rabbits) the AUC exposure at an adult human dose of 100 mg per day. However, fetal weights were decreased and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with an AUC exposure at the no-effect dose that is 4.5-times the AUC exposure at an adult human dose of 100 mg per day.

8.2 Lactation

Risk Summary

Data from published literature report the presence of venlafaxine and its active metabolite in human milk and have not shown adverse reactions in breastfed infants (see *Data*). There are no data on the effects of venlafaxine on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for venlafaxine hydrochloride extended-release capsules and any potential adverse effects on the breastfed child from venlafaxine hydrochloride extended-release capsules or from the underlying maternal condition.

Data

In a lactation study conducted in 11 breastfeeding women (at a mean of 20.1 months

post-partum) who were taking a mean daily dose of 194.3 mg of venlafaxine and in a lactation study conducted in 6 breastfeeding women who were taking a daily dose of 225 mg to 300 mg of venlafaxine (at a mean of 7 months post-partum), the estimated mean relative infant dose was 8.1 % and 6.4% based on the sum of venlafaxine and its major metabolite, desvenlafaxine. No adverse reactions were seen in the infants.

8.4 Pediatric Use

Safety and effectiveness of venlafaxine hydrochloride extended-release capsules in pediatric patients have not been established.

Two placebo-controlled trials in 766 pediatric patients with MDD and two placebo-controlled trials in 793 pediatric patients with GAD have been conducted with venlafaxine hydrochloride extended-release capsules, and the data were not sufficient to support use in pediatric patients.

In the studies conducted in pediatric patients ages 6 to 17 years, the occurrence of blood pressure and cholesterol increases was considered to be clinically relevant in pediatric patients and was similar to that observed in adult patients [see *Warnings and Precautions* (5.3), *Adverse Reactions* (6.1)]. The following adverse reactions were also observed in pediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.

Although no studies have been designed to primarily assess venlafaxine hydrochloride extended-release capsules impact on the growth, development, and maturation of children and adolescents, the studies that have been done suggest that venlafaxine hydrochloride extended-release capsules may adversely affect weight and height [see *Warnings and Precautions* (5.10, 5.11)]. Decreased appetite and weight loss were observed in placebo-controlled studies of pediatric patients 6 to 17 years.

In pediatric clinical studies, the adverse reaction, suicidal ideation, was observed. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see *Boxed Warning*, *Warnings and Precautions* (5.1)].

8.5 Geriatric Use

The percentage of patients in clinical studies for venlafaxine hydrochloride extended-release capsules for MDD, GAD, SAD, and PD who were 65 years of age or older are shown in Table 16.

Table 16: Percentage (and Number of Patients Studied) of Patients 65 Years of Age and Older by Indication^a

Indication	Venlafaxine Hydrochloride Extended-Release Capsules
MDD	4 (14/357)
GAD	6 (77/1,381)
SAD	1 (10/819)
PD	2 (16/1,001)

^a In addition, in the premarketing assessment of venlafaxine tablets (immediate release), 12% (357/2,897) of patients were ≥ 65 years of age.

No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including venlafaxine hydrochloride extended-release capsules, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see *Warnings and Precautions* (5.9)].

The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly [see *Clinical Pharmacology* (12.3)] (see Figure 1). No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction [see *Dosage and Administration* (2.8, 2.9)].

8.6 Hepatic Impairment

Dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment or hepatic cirrhosis [see *Dosage and Administration* (2.8) and *Clinical Pharmacology* (12.3)].

8.7 Renal Impairment

Dosage adjustment is recommended in patients with mild (CLcr= 60 to 89 mL/min), moderate (CLcr= 30 to 59 mL/min), or severe (CLcr < 30 mL/min) renal impairment, and in patients undergoing hemodialysis [see *Dosage and Administration* (2.9) and *Clinical Pharmacology* (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Venlafaxine hydrochloride extended-release capsules contain venlafaxine which is not a controlled substance.

9.2 Abuse

Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.

While venlafaxine has not been systematically studied in clinical studies for its potential for abuse, there was no indication of drug-seeking behavior in the clinical studies. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, providers should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

9.3 Dependence

Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.

In vitro studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (PCP), or N-methyl-D-aspartic acid (NMDA) receptors.

Venlafaxine was not found to have any significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability. Discontinuation effects have been reported in patients receiving venlafaxine [see *Dosage and Administration* (2.10) and *Warnings and Precautions* (5.7)].

10 OVERDOSAGE

Human Experience

During the premarketing evaluations of venlafaxine hydrochloride extended-release capsules (for MDD, GAD, SAD, and PD) and venlafaxine tablets (for MDD), there were twenty reports of acute overdose with venlafaxine tablets (6 and 14 reports in venlafaxine hydrochloride extended-release capsule and venlafaxine tablet patients, respectively), either alone or in combination with other drugs and/or alcohol.

Somnolence was the most commonly reported symptom. Among the other reported symptoms were paresthesia of all four limbs, moderate dizziness, nausea, numb hands and feet, and hot-cold spells 5 days after the overdose. In most cases, no signs or symptoms were associated with overdose. The majority of the reports involved ingestion in which the total dose of venlafaxine taken was estimated to be no more than several-fold higher than the usual therapeutic dose. One patient who ingested 2.75 g of venlafaxine was observed to have two generalized convulsions and a prolongation of QTc to 500 msec, compared with 405 msec at baseline. Mild sinus tachycardia was reported in two of the other patients.

Actions taken to treat the overdose included no treatment, hospitalization and symptomatic treatment, and hospitalization plus treatment with activated charcoal. All patients recovered.

In postmarketing experience, overdose with venlafaxine has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.

Published retrospective studies report that venlafaxine overdose may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher preexisting burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdose, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. Prescriptions for venlafaxine hydrochloride extended-release capsules should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.


Management of Overdosage

No specific antidotes for venlafaxine hydrochloride extended-release capsules are known. In managing overdose, consider the possibility of multiple drug involvement. Consider contacting a Poison Center (1-800-222-1222) or a medical toxicologist for overdose management recommendations for venlafaxine hydrochloride extended-release capsules.

11 DESCRIPTION

Venlafaxine hydrochloride extended-release capsules, USP are an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride, USP a serotonin and norepinephrine reuptake inhibitor (SNRI).

Venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p-methoxybenzyl]cyclohexanol hydrochloride and has the molecular formula of $C_{17}H_{27}NO_2 \cdot HCl$. Its molecular weight is 313.86. The structural formula is shown as follows:



Venlafaxine hydrochloride, USP is a white to off-white crystalline solid, with a solubility of 572 mg/mL in water (adjusted to ionic strength of 0.2 M with sodium chloride). Its octanol:water (0.2 M sodium chloride) partition coefficient is 0.43.

Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent. Capsules contain venlafaxine hydrochloride, USP equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of black iron oxide, dibutyl sebacate, ethylcellulose, gelatin, polyethylene glycol, povidone, propylene glycol, shellac, sugar spheres (which contain sucrose and corn starch), FD&C Yellow No. 6, Sunset Yellow FCF, talc, and titanium dioxide. The 37.5 mg capsules also contain D&C Yellow No. 10 and potassium hydroxide, the 75 mg capsules also contain D&C Yellow No. 10 and may contain potassium hydroxide, and the 150 mg capsules also contain potassium hydroxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.

12.2 Pharmacodynamics

In-vitro studies have demonstrated that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent and selective inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant affinity for muscarinic-cholinergic, H_1 -histaminergic, or α_1 -

adrenergic receptors *in vitro*. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory activity.

Cardiac Electrophysiology

The effect of venlafaxine on the QT interval was evaluated in a randomized, double-blind, placebo- and positive-controlled three-period crossover thorough QT study in 54 healthy adult subjects. No significant QT prolongation effect of venlafaxine at 450 mg (2 times the maximum recommended dosage) was detected.

12.3 Pharmacokinetics

Venlafaxine and ODV steady-state concentrations are reached within 3 days. Venlafaxine and ODV exhibited linear kinetics over the dosage range of 75 mg to 450 mg per day (0.33 to 2 times the maximum recommended dosage). Time of administration (AM versus PM) did not affect the pharmacokinetics of venlafaxine and ODV from the 75 mg venlafaxine hydrochloride extended-release capsules.

Absorption

Venlafaxine is well absorbed. On the basis of mass balance studies, at least 92% of a single oral dose of venlafaxine is absorbed. The absolute bioavailability of venlafaxine is approximately 45%.

Administration of venlafaxine hydrochloride extended-release capsules (150 mg once daily) generally resulted in lower C_{max} and later T_{max} values than for venlafaxine tablets (immediate release) administered twice daily (Table 17). When equal daily doses of venlafaxine were administered as either an immediate-release tablet or the extended-release capsule, the exposure to both venlafaxine and ODV was similar for the two treatments, and the fluctuation in plasma concentrations was slightly lower with the venlafaxine hydrochloride extended-release capsules. Therefore, venlafaxine hydrochloride extended-release capsules provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet.

Table 17: Comparison of C_{max} and T_{max} Values for Venlafaxine and ODV Following Oral Administration of Venlafaxine Hydrochloride Extended-Release Capsules and Venlafaxine Tablets (Immediate Release)

	Venlafaxine		ODV	
	C_{max} (ng/mL)	T_{max} (h)	C_{max} (ng/mL)	T_{max} (h)
Venlafaxine Hydrochloride Extended-Release Capsules (150 mg once daily)	150	5.5	260	9
Venlafaxine Tablets (75 mg twice daily)	225	2	290	3

Effect of Food

Food did not affect the bioavailability of venlafaxine or its active metabolite, ODV.

Distribution

Venlafaxine is 27% and ODV is 30% bound to plasma proteins. The apparent volume of distribution at steady-state is 7.5 ± 3.7 L/kg for venlafaxine and 5.7 ± 1.8 L/kg for ODV.

Elimination

Mean \pm SD plasma apparent clearance at steady-state is 1.3 ± 0.6 L/h/kg for venlafaxine and 0.4 ± 0.2 L/h/kg for ODV. The apparent elimination half-life is 5 ± 2 hours for venlafaxine and 11 ± 2 hours for ODV.

Metabolism

Following absorption, venlafaxine undergoes extensive presystemic metabolism in the liver, primarily to ODV, but also to N-desmethylvenlafaxine, N,O-didesmethylvenlafaxine, and other minor metabolites. *In vitro* studies indicate that the formation of ODV is

catalyzed by CYP2D6; this has been confirmed in a clinical study showing that patients with low CYP2D6 levels (poor metabolizers) had increased levels of venlafaxine and reduced levels of ODV compared to people with normal CYP2D6 levels (extensive metabolizers) (see Figure 1).


Excretion

Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).

Specific Populations

The effect of intrinsic patient factors on the pharmacokinetics of venlafaxine and its active metabolite ODV is presented in Figure 1.

Figure 1: Pharmacokinetics of Venlafaxine and Active Metabolite O-desmethylvenlafaxine (ODV) in Special Populations



ODV=O-desmethylvenlafaxine; AUC=area under the curve; C_{max}=peak plasma concentrations.

* Similar effect is expected with strong CYP2D6 inhibitors


Drug Interaction Studies

Clinical Studies

Effect of Other Drugs On Venlafaxine Hydrochloride Extended-Release Capsules and Active Metabolite ODV

The effects of other drugs on the exposure of venlafaxine and ODV are summarized in Figure 2.

Figure 2: Effect of Other Drugs on the Pharmacokinetics of Venlafaxine and Active Metabolite O-desmethylvenlafaxine (ODV)




ODV=O-desmethylvenlafaxine; AUC=area under the curve; C_{max}=peak plasma concentrations; EM's=extensive metabolizers; PM's=poor metabolizers.

Effect of Venlafaxine Hydrochloride Extended-Release Capsules on Other Drugs

The effects of venlafaxine hydrochloride extended-release capsules on the exposure of other drugs are summarized in Figure 3.

Figure 3: Effect of Venlafaxine on the Pharmacokinetics Interacting Drugs and their Active Metabolites



AUC=area under the curve; C_{max}=peak plasma concentrations; OH=hydroxyl.

* Data for 2-OH desipramine were not plotted to enhance clarity; the fold change and 90% CI for C_{max} and AUC of 2-OH desipramine were 6.6 (5.5, 7.9) and 4.4 (3.8, 5.0), respectively.

Note:* Administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Tumors were not increased by venlafaxine treatment in mice or rats. Venlafaxine was given by oral gavage to mice for 18 months at doses up to 120 mg/kg per day, which was 1.7 times the maximum recommended human dose on a mg/m² basis. Venlafaxine was also given to rats by oral gavage for 24 months at doses up to 120 mg/kg per day. In rats receiving the 120 mg/kg dose, plasma concentrations of venlafaxine at necropsy were 1 times (male rats) and 6 times (female rats) the plasma concentrations of patients receiving the maximum recommended human dose. Plasma levels of the ODV were lower in rats than in patients receiving the maximum recommended dose. ODV, the major human metabolite of venlafaxine, administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study. Mice received ODV at dosages up to 500/300 mg/kg/day (dosage lowered after 45 weeks of dosing). The exposure at the 300 mg/kg/day dose is 9 times that of a human dose of 225 mg/day. Rats received ODV at dosages up to 300 mg/kg/day (males) or 500 mg/kg/day (females). The exposure at the highest dose is approximately 8 (males) or 11 (females) times that of a human dose of 225 mg/day.

Mutagenesis

Venlafaxine and the major human metabolite, ODV, were not mutagenic in the Ames reverse mutation assay in *Salmonella* bacteria or the Chinese hamster ovary/HGPRT mammalian cell forward gene mutation assay. Venlafaxine was also not mutagenic or clastogenic in the *in vitro* BALB/c-3T3 mouse cell transformation assay, the sister chromatid exchange assay in cultured Chinese hamster ovary cells, or in the *in vivo*

chromosomal aberration assay in rat bone marrow. ODV was not clastogenic in the *in vitro* Chinese hamster ovary cell chromosomal aberration assay or in the *in vivo* chromosomal aberration assay in rats.

Impairment of Fertility

Reproduction and fertility studies of venlafaxine in rats showed no adverse effects of venlafaxine on male or female fertility at oral doses of up to 2 times the maximum recommended human dose of 225 mg/day on a mg/m² basis. However, when desvenlafaxine succinate, the major human metabolite of venlafaxine, was administered orally to male and female rats, fertility was reduced at the high dose of 300 mg/kg/day, which is 10 (males) and 19 (females) times the AUC exposure at an adult human dose of 100 mg per day. There was no effect on fertility at 100 mg/kg/day, which is 3 (males) or 5 (females) times the AUC exposure at an adult human dose of 100 mg per day. These studies did not address reversibility of the effect on fertility. The relevance of these findings to humans is not known.

14 CLINICAL STUDIES

14.1 Major Depressive Disorder

The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Major Depressive Disorder (MDD) was established in two placebo-controlled, short-term (8 weeks for study 1; 12 weeks for study 2), flexible-dose studies, with doses starting at 75 mg per day and ranging to 225 mg per day in adult outpatients meeting DSM-III-R or DSM-IV criteria for MDD. In moderately depressed outpatients, the initial dose of venlafaxine was 75 mg per day. In both studies, venlafaxine hydrochloride extended-release capsules demonstrated superiority over placebo on the primary efficacy measure defined as change from baseline in the HAM-D-21 total score to the endpoint visit, venlafaxine hydrochloride extended-release capsules also demonstrated superiority over placebo on the key secondary efficacy endpoint, the Clinical Global Impressions (CGI) Severity of Illness scale. Examination of gender subsets of the population studied did not reveal any differential responsiveness on the basis of gender.

A 4-week study of inpatients meeting DSM-III-R criteria for MDD with melancholia utilizing venlafaxine tablets in a range of 150 mg to 375 mg per day (divided in a three-times-a-day schedule) demonstrated superiority of venlafaxine hydrochloride tablets over placebo based on the HAM-D-21 total score. The mean dose in completers was 350 mg per day (study 3).

In a longer-term study, adult outpatients with MDD who had responded during an 8-week open-label study on venlafaxine hydrochloride extended-release capsules (75 mg, 150 mg, or 225 mg, once daily every morning) were randomized to continuation of their same venlafaxine hydrochloride extended-release capsule dose or to placebo, for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a CGI Severity of Illness item score of ≤ 3 and a HAM-D-21 total score of ≤ 10 at the day 56 evaluation. Relapse during the double-blind phase was defined as follows: (1) a reappearance of major depressive disorder as defined by DSM-IV criteria and a CGI Severity of Illness item score of ≥ 4 (moderately ill), (2) 2 consecutive CGI Severity of Illness item scores of ≥ 4 , or (3) a final CGI Severity of Illness item score of ≥ 4 for any patient who withdrew from the study for any reason. Patients receiving continued venlafaxine hydrochloride extended-release capsule treatment experienced statistically significantly lower relapse rates over the subsequent 26 weeks compared with those receiving placebo (study 4).

In a second longer term trial, adult outpatients with MDD, recurrent type, who had responded (HAM-D-21 total score ≤ 12 at the day 56 evaluation) and continued to be improved [defined as the following criteria being met for days 56 through 180: (1) no HAM-D-21 total score ≥ 20 ; (2) no more than 2 HAM-D-21 total scores > 10 , and (3) no single CGI Severity of Illness item score ≥ 4 (moderately ill)] during an initial 26 weeks of treatment on venlafaxine tablets [100 mg to 200 mg per day, on a twice daily schedule] were randomized to continuation of their same venlafaxine tablet dose or to placebo. The follow-up period to observe patients for relapse, defined as a CGI Severity of Illness item score ≥ 4 , was for up to 52 weeks. Patients receiving continued venlafaxine tablet treatment experienced statistically significantly lower relapse rates over the subsequent 52 weeks compared with those receiving placebo (study 5).

Table 18: Primary Efficacy Results for Studies in Major Depressive Disorder in Adults (Studies 1, 2, 3)

Study Number	Treatment Group	Primary Efficacy Measure: HAM-D Score
---------------------	------------------------	--

		Mean Baseline Score (SD)	LS Mean Change from Baseline	Placebo Subtracted Difference ^a (95% CI)
Study 1	Venlafaxine Hydrochloride Extended-Release Capsules(75 to 225 mg/day)*	24.5	-11.7	-4.45 (-6.66, -2.25)
	Placebo	23.6	-7.24	-
Study 2	Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg/day)*	24.5	-15.11	-6.40 (-8.45, -4.34)
	Placebo	24.9	-8.71	-
Study 3	Venlafaxine Immediate Release Tablets (150 to 375 mg/day)*	28.2 (0.5)	-14.9	-10.2 (-14.4, -6.0)
	Placebo	28.6 (0.6)	-4.7	-

SD=standard deviation; LS Mean=least-squares mean; CI=confidence interval.
^a Difference (drug minus placebo) in least-squares mean change from baseline
* Doses statistically significantly superior to placebo.

14.2 Generalized Anxiety Disorder

The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Generalized Anxiety Disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 mg to 225 mg per day), one 6-month, placebo-controlled, flexible-dose study (75 mg to 225 mg per day), and one 6-month, placebo-controlled, fixed-dose study (37.5 mg, 75 mg, and 150 mg per day) in adult outpatients meeting DSM-IV criteria for GAD.

In one 8-week study, venlafaxine hydrochloride extended-release capsules demonstrated superiority over placebo for the 75 mg, 150 mg, and 225 mg per day doses as measured by the Hamilton Rating Scale for Anxiety (HAM-A) total score, both the HAM-A anxiety and tension items, and the Clinical Global Impressions (CGI) scale. However, the 75 mg and 150 mg per day doses were not as consistently effective as the highest dose (study 1). A second 8-week study evaluating doses of 75 mg and 150 mg per day and placebo showed that both doses were more effective than placebo on some of these same outcomes; however, the 75 mg per day dose was more consistently effective than the 150 mg per day dose (study 2). A dose-response relationship for effectiveness in GAD was not clearly established in the 75 mg to 225 mg per day dose range studied.

Two 6-month studies, one evaluating venlafaxine hydrochloride extended-release capsule doses of 37.5 mg, 75 mg, and 150 mg per day (study 3) and the other evaluating venlafaxine hydrochloride extended-release capsules doses of 75 mg to 225 mg per day (study 4), showed that daily doses of 75 mg or higher were more effective than placebo on the HAM-A total, both the HAM-A anxiety and tension items, and the CGI scale during 6 months of treatment. While there was also evidence for superiority over placebo for the 37.5 mg per day dose, this dose was not as consistently effective as the higher doses.

Examination of gender subsets of the population studied did not reveal any differential responsiveness on the basis of gender.

Table 19: Primary Efficacy Results for Studies in Generalized Anxiety Disorder in Adults (Studies 1, 2, 3, 4)

Study Number	Treatment Group	Primary Efficacy Measure: HAM-A Score		
		Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)*	Placebo Subtracted Difference ^a (95% CI)

Study 1	Venlafaxine HCl Extended-Release Capsules 75 mg	24.7	-11.1 (0.95)	-1.5 (-3.8, 0.8)
	Venlafaxine HCl Extended-Release Capsules 150 mg	24.5	-11.7 (0.87)	-2.2 (-4.5, 0.1)
	Venlafaxine HCl Extended-Release Capsules 225 mg	23.6	-12.1 (0.81)	-2.6 (-4.9, -0.3)
	Placebo	24.1	-9.5 (0.85)	
Study 2	Venlafaxine HCl Extended-Release Capsules 75 mg	23.7	-10.6 (0.82)	-2.6 (-4.6, -0.5)
	Venlafaxine HCl Extended-Release Capsules 150 mg	23.0	-9.8 (0.86)	-1.7 (-3.8, 0.3)
	Placebo	23.7	-8.0 (0.73)	
Study 3	Venlafaxine HCl Extended-Release Capsules 37.5 mg	26.6 (0.4)	-13.8	-2.8 (-5.1, -0.6)
	Venlafaxine HCl Extended-Release Capsules 75 mg	26.3 (0.4)	-15.5	-4.6 (-6.9, -2.3)
	Venlafaxine HCl Extended-Release Capsules 150 mg	26.3 (0.4)	-16.4	-5.5 (-7.8, -3.1)
	Placebo	26.7 (0.5)	-11.0	
Study 4	Venlafaxine HCl Extended-Release Capsules 75 to 225 mg	25.0	-13.4 (0.79)	-4.7 (-6.6, -2.9)
	Placebo	24.9	-8.7 (0.70)	

SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=confidence interval.
^a Difference (drug minus placebo) in least-squares mean change from baseline
* Doses statistically significantly superior to placebo.

14.3 Social Anxiety Disorder (also known as Social Phobia)

The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Social Anxiety Disorder (SAD) was established in four double-blind, parallel-group, 12-week, multicenter, placebo-controlled, flexible-dose studies (studies 1 to 4) and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study, which included doses in a range of 75 mg to 225 mg per day in adult outpatients meeting DSM-IV criteria for SAD (study 5).

In these five studies, venlafaxine hydrochloride extended-release capsules were statistically significantly more effective than placebo on change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) total score. There was no evidence for any greater effectiveness of the 150 mg to 225 mg per day group compared to the 75 mg per day group in the 6-month study.

Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.

Table 20: Primary Efficacy Results for Studies in Social Anxiety Disorder in Adults (Studies 1, 2, 3, 4, 5)

Study Number	Treatment Group	Primary Efficacy Measure: LSAS Score		
		Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo Subtracted Difference ^a (95% CI)
Study 1	Venlafaxine HCl Extended-Release Capsules (75 to 225 mg)*	91.1	-31.0 (2.22)	11.2 (-5.3, -17.1)
	Placebo	86.7	-19.9 (2.22)	-
Study 2	Venlafaxine HCl Extended-Release Capsules (75 to 225 mg)*	90.8	-32.8 (2.69)	-10.7 (-3.7, -17.6)
	Placebo	87.4	-22.1 (2.66)	-
	Venlafaxine HCl Extended-Release Capsules	82.2	-36.0 (2.35)	-16.0 (-22.6, -11.2)

Study 3	(75 to 225 mg)*	85.2	-30.0 (2.55)	-10.9 (-22.0, -11.2)
	Placebo	83.6	-19.1 (2.40)	-12.7 (-6.5, -19.0)
Study 4	Venlafaxine HCl Extended-Release Capsules (75 to 225 mg)*	86.2	-35.0 (2.64)	-14.6 (-21.8, -7.4)
	Placebo	86.1	-22.2 (2.47)	
Study 5	Venlafaxine HCl Extended-Release Capsules 75 mg	91.8	-38.1 (3.16)	-14.6 (-21.8, -7.4)
	Venlafaxine HCl Extended-Release Capsules (150 to 225 mg)*	86.2	-37.6 (3.05)	-14.1 (-21.3, -6.9)
	Placebo	89.3	-23.5 (3.08)	

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval.

^a Difference (drug minus placebo) in least-squares mean change from baseline

* Doses statistically significantly superior to placebo.

14.4 Panic Disorder

The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Panic Disorder (PD) was established in two double-blind, 12-week, multicenter, placebo-controlled studies in adult outpatients meeting DSM-IV criteria for PD, with or without agoraphobia. Patients received fixed doses of 75 mg or 150 mg per day in one study (study 1) and 75 mg or 225 mg per day in the other study (study 2).

Efficacy was assessed on the basis of outcomes in three variables: (1) percentage of patients free of full-symptom panic attacks on the Panic and Anticipatory Anxiety Scale (PAAS); (2) mean change from baseline to endpoint on the Panic Disorder Severity Scale (PDSS) total score; and (3) percentage of patients rated as responders (much improved or very much improved) on the Clinical Global Impressions (CGI) Improvement scale. In these two studies, venlafaxine hydrochloride extended-release capsules were statistically significantly more effective than placebo (for each fixed dose) on all three endpoints, but a dose-response relationship was not clearly established.

Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.

In a longer term study (study 3), adult outpatients meeting DSM-IV criteria for PD who had responded during a 12-week open phase with venlafaxine hydrochloride extended-release capsules (75 mg to 225 mg per day) were randomly assigned to continue the same venlafaxine hydrochloride extended-release capsules dose (75 mg, 150 mg, or 225 mg) or switch to placebo for observation for relapse under double-blind conditions. Response during the open phase was defined as ≤ 1 full-symptom panic attack per week during the last 2 weeks of the open phase and a CGI Improvement score of 1 (very much improved) or 2 (much improved). Relapse during the double-blind phase was defined as having 2 or more full-symptom panic attacks per week for 2 consecutive weeks or having discontinued due to loss of effectiveness as determined by the investigators during the study. Randomized patients were in response status for a mean time of 34 days prior to being randomized. In the randomized phase following the 12-week open-label period, patients receiving continued venlafaxine hydrochloride extended-release capsules experienced a statistically significantly longer time to relapse.

Table 21: Primary Efficacy Results for Studies in Panic Disorder in Adults (Studies 1 and 2)

Study Number	Treatment Group	Primary Efficacy Measure: Whether Free of Full-symptom Panic Attacks		
		Percent of patients Free of Full symptom panic attack	Adjusted Odds Ratio ^a to placebo	Adjusted Odds Ratio ^a 95% Confidence Interval
Study 1	Venlafaxine HCl Extended-Release Capsules 75 mg*	54.1% (85/157)	2.268	(1.43, 3.59)
	Venlafaxine HCl Extended-Release Capsules 150 mg*	61.4% (97/158)	3.035	(1.91, 4.82)
	Placebo	34.4% (53/154)	--	--
	Venlafaxine HCl Extended-			(1.46,

Study 2	Release Capsules 75 mg*	64.1% (100/156)	2.350	3.78)
	Venlafaxine HCl Extended-Release Capsules 225 mg*	70.0% (112/160)	2.890	(1.80,
				4.64)
	Placebo	46.5% (73/157)	--	--

^a Odds ratio (drug to placebo) in terms of probability of free of full-symptom panic attacks based on logistic regression model.
95% CI: 95% confidence interval without adjusting for multiple dose arms.
* Doses statistically significantly superior to placebo.

16 HOW SUPPLIED/STORAGE AND HANDLING

Venlafaxine hydrochloride extended-release capsules, USP are available as follows:

37.5 mg - Light-gray opaque cap/buff opaque body with “93” and “7384” on both body and cap. Capsules are available in bottles of 30 (NDC 0093-7384-56), 90 (NDC 0093-7384-98), and 500 (NDC 0093-7384-05).

75 mg - Buff opaque cap/buff opaque body with “93” and “7385” on both body and cap. Capsules are available in bottles of 30 (NDC 0093-7385-56), 90 (NDC 0093-7385-98), and 500 (NDC 0093-7385-05).

150 mg - Light-orange opaque cap/light-orange opaque body with “93” and “7386” on both body and cap. Capsules are available in bottles of 30 (NDC 0093-7386-56), 90 (NDC 0093-7386-98), and 500 (NDC 0093-7386-05).

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Keep this and all medications out of the reach of children.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behaviors

Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down, and instruct them to report such symptoms to the healthcare provider [see *Boxed Warning and Warnings and Precautions* (5.1)].

Concomitant Medication

Instruct patients not to take venlafaxine hydrochloride extended-release capsules with an MAOI or within 14 days of stopping an MAOI [see *Contraindications* (4)].

Serotonin Syndrome

Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [see *Warnings and Precautions* (5.2) and *Drug Interactions* (7.1)].

Elevated Blood Pressure

Advise patients that they should have regular monitoring of blood pressure when taking venlafaxine hydrochloride extended-release capsules [see *Warnings and Precautions* (5.3)].

Increased Risk of Bleeding

Inform patients about the concomitant use of venlafaxine hydrochloride extended-release capsules and NSAIDs, aspirin, other antiplatelet drugs, warfarin, or other drugs that affect coagulation because the combined use has been associated with an increased risk of bleeding. Advise patients to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding [see *Warnings and Precautions* (5.4)].

Activation of Mania/Hypomania

Advise patients, their families and caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider [see *Warnings and Precautions* (5.6)].

Cardiovascular/Cerebrovascular Disease

Caution is advised in administering venlafaxine hydrochloride extended-release capsules to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders [see *Adverse Reactions* (6.1)].

Serum Cholesterol and Triglyceride Elevation

Advise patients that elevations in total cholesterol, LDL and triglycerides may occur and that measurement of serum lipids may be considered [see *Adverse Reactions* (6.1)].

Discontinuation Syndrome

Advise patients not to abruptly stop taking venlafaxine hydrochloride extended-release capsules without talking first with their healthcare provider. Patients should be aware that discontinuation effects may occur when stopping venlafaxine hydrochloride extended-release capsules and they should monitor for discontinuation symptoms [see *Warnings and Precautions* (5.7) and *Adverse Reactions* (6.1)].

Sexual Dysfunction

Advise patients that use of venlafaxine hydrochloride extended-release capsules may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider [see *Warnings and Precautions* (5.13)].

Interference with Cognitive and Motor Performance

Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that venlafaxine hydrochloride extended-release capsules therapy does not adversely affect their ability to engage in such activities.

Alcohol

Advise patients to avoid alcohol while taking venlafaxine hydrochloride extended-release capsules [see *Drug Interactions* (7.2)].

Allergic Reactions

Advise patients to notify their healthcare provider if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing [see *Contraindications* (4) and *Adverse Reactions* (6.2)].

Pregnancy

Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with venlafaxine hydrochloride extended-release capsules. Advise patients that venlafaxine hydrochloride extended-release capsule use during mid to late pregnancy may lead to an increased risk for preeclampsia; use in late pregnancy may lead to an increased risk for postpartum hemorrhage and may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to venlafaxine hydrochloride extended-release capsules during pregnancy [see *Use in Specific Populations* (8.1)].

Residual Spheroids

Venlafaxine hydrochloride extended-release capsules contain spheroids, which release the drug slowly into the digestive tract. The insoluble portion of these spheroids is eliminated, and patients may notice spheroids passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the spheroids.

Dispense with Medication Guide available at: www.tevausa.com/medguides

Manufactured In Israel By:

Teva Pharmaceutical Ind. Ltd.

Kfar Saba, 4410202, Israel

Manufactured For:

Teva Pharmaceuticals

Parsippany, NJ 07054

Rev. Q 9/2022

MEDICATION GUIDE
Venlafaxine Hydrochloride (ven' la fax' een hye' droe klor' ide)
Extended-Release Capsules

What is the most important information I should know about venlafaxine hydrochloride extended-release capsules?

Venlafaxine hydrochloride extended-release capsules may cause serious side effects, including:

- **Increased risk of suicidal thoughts and actions** Venlafaxine hydrochloride extended-release capsules and other antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults, **especially within the first few months of treatment or when the dose is changed. Venlafaxine hydrochloride extended-release capsules are not for use in children.**
 - Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

- Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
- Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
- Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call your healthcare provider or get emergency help right away if you or a family member have any of the following symptoms, especially if they are new, worse, or worry you:

- | | |
|--|---|
| • attempts to commit suicide | • thoughts about suicide or dying |
| • acting aggressive, being angry, or violent | • acting on dangerous impulses |
| • new or worse depression | • new or worse anxiety |
| • panic attacks | • feeling very agitated or restless |
| • new or worse irritability | • trouble sleeping |
| • an extreme increase in activity or talking (mania) | • other unusual changes in behavior or mood |

What are venlafaxine hydrochloride extended-release capsules?

Venlafaxine hydrochloride extended-release capsules are a prescription medicine used to treat adults with

- a certain type of depression called Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Social Anxiety Disorder (SAD)
- Panic Disorder (PD)

It is not known if venlafaxine hydrochloride extended-release capsules are safe and effective for use in children.

Do not take venlafaxine hydrochloride if you:

- are allergic to venlafaxine hydrochloride, desvenlafaxine succinate, or any of the ingredients in venlafaxine hydrochloride extended-release capsules. See the end of this Medication Guide for a complete list of ingredients in venlafaxine hydrochloride extended-release capsules.
- take a Monoamine Oxidase Inhibitor (MAOI)
- have stopped taking an MAOI in the last 14 days
- are being treated with the antibiotic linezolid or intravenous methylene blue

Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including MAOIs such as linezolid or intravenous methylene blue.

Do not start taking an MAOI for at least 7 days after you stop treatment with venlafaxine hydrochloride extended-release capsules.

Before taking venlafaxine hydrochloride extended-release capsules tell your healthcare provider about all your medical conditions, including if you:

- have, or have a family history of suicide, bipolar disorder, depression, mania or hypomania
- have high blood pressure
- have heart problems
- have cerebrovascular problems or had a stroke
- have or have had bleeding problems
- have high pressure in the eye (glaucoma)
- have high cholesterol or high triglycerides
- have kidney or liver problems
- have or had seizures or convulsions

- have low sodium levels in your blood
- have lung problems
- drink alcohol
- are pregnant or plan to become pregnant. Venlafaxine hydrochloride extended-release capsules may harm your unborn baby. Talk to your healthcare provider about the risk to you and your unborn baby if you take venlafaxine hydrochloride extended-release capsules during pregnancy.
 - Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with venlafaxine hydrochloride extended-release capsules.
 - **Pregnancy Exposure Registry.** There is a pregnancy registry for women who are exposed to venlafaxine hydrochloride extended-release capsules during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with venlafaxine hydrochloride extended-release capsules, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-6185 or by visiting online at <https://womensmentalhealth.org/research/pregnancyregistry/antidepressants>.
- are breastfeeding or plan to breastfeed. Venlafaxine hydrochloride passes into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with venlafaxine hydrochloride extended-release capsules.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Venlafaxine hydrochloride extended-release capsules and other medicines may affect each other causing possible serious side effects. Venlafaxine hydrochloride extended-release capsules may affect the way other medicines work and other medicines may affect the way venlafaxine hydrochloride extended-release capsules work.

Especially tell your healthcare provider if you take:

- medicines to treat migraine headaches known as triptans
- tricyclic antidepressants
- fentanyl
- lithium
- tramadol
- tryptophan
- buspirone
- amphetamines
- St. John's Wort
- phentermine
- other medicines containing desvenlafaxine or venlafaxine
- medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin

Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take venlafaxine hydrochloride extended-release capsules with your other medicines.

Do not start or stop any other medicines during treatment with venlafaxine hydrochloride extended-release capsules without first talking to your healthcare provider. Stopping venlafaxine hydrochloride extended-release capsules suddenly may cause you to have serious side effects. See, **“What are the possible side effects of venlafaxine hydrochloride extended-release capsules?”**

Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How should I take venlafaxine hydrochloride extended-release capsules?

- Take venlafaxine hydrochloride extended-release capsules exactly as your healthcare provider tells you to. Do not change your dose or stop taking venlafaxine hydrochloride extended-release capsules without first talking to your healthcare provider.
- Your healthcare provider may need to change the dose of venlafaxine hydrochloride extended-release capsules until it is the right dose for you.
- Take venlafaxine hydrochloride extended-release capsules 1 time each day with food.
- Venlafaxine hydrochloride extended-release capsules may be taken either in the morning or in the evening, but take it the same way each time.
- Swallow venlafaxine hydrochloride extended-release capsules whole with fluid. Do not divide, crush, chew, or dissolve venlafaxine hydrochloride extended-release capsules.
- If you cannot swallow venlafaxine hydrochloride extended-release capsules whole, the venlafaxine hydrochloride extended-release capsules may be opened and the entire contents sprinkled on a spoonful of applesauce.
 - Swallow the venlafaxine hydrochloride extended-release capsules and applesauce mixture right away without chewing.
 - Follow with a glass of water to make sure you have swallowed all of the venlafaxine hydrochloride extended-release capsules pellets.
- If you take too much venlafaxine hydrochloride extended-release capsules, call healthcare provider or poison control center at 1-800-222-1222 or go to the nearest hospital emergency room right away.

What should I avoid while taking venlafaxine hydrochloride extended-release capsules?

- Do not drive, or operate heavy machinery, or do other dangerous activities until you know how venlafaxine hydrochloride extended-release capsules affects you. Venlafaxine hydrochloride extended-release capsules can make you drowsy.
- You should not drink alcohol during treatment with venlafaxine hydrochloride extended-release capsules. Drinking alcohol

during treatment with venlafaxine hydrochloride extended-release capsules can increase your risk of having serious side effects.

What are the possible side effects of venlafaxine hydrochloride extended-release capsules?

Venlafaxine hydrochloride extended-release capsules may cause serious side effects, including:

- See, **“What is the most important information I should know about venlafaxine hydrochloride extended-release capsules?”**
- **Serotonin syndrome.** Taking venlafaxine hydrochloride extended-release capsules can cause a potentially life-threatening problem called serotonin syndrome. The risk of developing serotonin syndrome is increased when venlafaxine hydrochloride extended-release capsules it taken with certain other medicines. See, **“Do not take venlafaxine hydrochloride extended-release capsules if you:”** Stop taking venlafaxine hydrochloride extended-release capsules and call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of serotonin syndrome:
 - agitation
 - confusion
 - fast heartbeat
 - dizziness
 - flushing
 - tremors, stiff muscles, or muscle twitching
 - seizures
 - seeing or hearing things that are not real (hallucinations)
 - coma
 - changes in blood pressure
 - sweating
 - high body temperature (hyperthermia)
 - loss of coordination
 - nausea, vomiting, diarrhea
- **Increases in blood pressure.** Your healthcare provider should check your blood pressure before starting treatment and regularly during treatment with venlafaxine hydrochloride extended-release capsules. If you have high blood pressure, it should be controlled before you start treatment with venlafaxine hydrochloride extended-release capsules.
- **Increased risk of bleeding.** Taking venlafaxine hydrochloride extended-release capsules with aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising.
- **Eye problems (angle-closure glaucoma).** Venlafaxine hydrochloride extended-release capsules may cause a certain type of eye problem called angle-closure glaucoma. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. Call your healthcare provider if you have eye pain, changes in your vision, or swelling or redness in or around the eye.
- **Manic episodes.** Manic episodes may happen in people with bipolar disorder who take venlafaxine hydrochloride extended-release capsules.

Symptoms may include:

- greatly increased energy
- racing thoughts
- unusually grand ideas
- talking more or faster than usual
- severe trouble sleeping
- reckless behavior
- excessive happiness or irritability
- **Discontinuation syndrome.** Suddenly stopping venlafaxine hydrochloride extended-release capsules may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include:
 - dizziness
 - irritability and agitation
 - anxiety
 - sweating
 - seizures
 - ringing in your ears (tinnitus)
 - nausea
 - problems sleeping
 - tiredness
 - confusion
 - electric shock sensation (paresthesia)
 - headache
 - diarrhea
 - abnormal dreams
 - changes in your mood
 - hypomania
- **Seizures (convulsions).**
- **Low sodium levels in your blood (hyponatremia).** Low sodium levels can happen during treatment with venlafaxine hydrochloride extended-release capsules. Low sodium levels in your blood may be serious and may cause death. Elderly people may be at greater risk for this. Signs and Symptoms of low sodium levels in your blood may include:
 - headache
 - difficulty concentrating
 - memory changes
 - confusion
 - weakness and unsteadiness on your feet which can lead to falls

In severe or more sudden cases, signs and symptoms include:

- hallucinations (seeing or hearing things that are not real)
- fainting
- seizures
- coma
- respiratory arrest

- **Lung problems.** Some people who have taken the medicine venlafaxine which is the same kind of medicine as the medicine in venlafaxine hydrochloride extended-release capsules have had lung problems. Symptoms of lung problems include difficulty breathing, cough, or chest discomfort. Tell your healthcare provider right away if you have any of these symptoms.
- **Sexual problems (dysfunction).** Taking selective serotonin reuptake inhibitors (SNRIs), including venlafaxine hydrochloride extended-release capsules, may cause sexual problems.

Symptoms in males may include:

- delayed ejaculation or inability to have an ejaculation
- decreased sex drive
- problems getting or keeping an erection

Symptoms in females may include:

- decreased sex drive
- delayed orgasm or inability to have an orgasm

Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with venlafaxine hydrochloride extended-release capsules. There may be treatments your healthcare provider can suggest.

Your healthcare provider may tell you to stop taking venlafaxine hydrochloride extended-release capsules if you develop serious side effects during treatment with venlafaxine hydrochloride extended-release capsules.

The most common side effects of venlafaxine hydrochloride extended-release capsules include:

- | | |
|-----------------------------------|----------------|
| • nausea | • sleepiness |
| • dry mouth | • sweating |
| • male and female sexual problems | • constipation |
| • loss of appetite (anorexia) | |

These are not all the possible side effects of venlafaxine hydrochloride extended-release capsules.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store venlafaxine hydrochloride extended-release capsules?

- Store venlafaxine hydrochloride extended-release capsules at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep venlafaxine hydrochloride extended-release capsules in a dry place.

Keep venlafaxine hydrochloride extended-release capsules and all medicines out of the reach of children.

General Information about venlafaxine hydrochloride extended-release capsules.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use venlafaxine hydrochloride extended-release capsules for a condition for which it was not prescribed. Do not give venlafaxine hydrochloride extended-release capsules to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about venlafaxine hydrochloride extended-release capsules that is written for healthcare professionals.

For more information about venlafaxine hydrochloride extended-release capsules call 1-888-838-2872.

What are the ingredients in venlafaxine hydrochloride extended-release capsules?

Active ingredient: venlafaxine hydrochloride.

Inactive ingredients: black iron oxide, dibutyl sebacate, ethylcellulose, gelatin, polyethylene glycol, povidone, propylene glycol, shellac, sugar spheres (which contain sucrose and corn starch), FD&C Yellow No. 6, Sunset Yellow FCF, talc, and titanium dioxide. The 37.5 mg capsules also contain D&C Yellow No.10 and potassium hydroxide, the 75 mg capsules also contain D&C Yellow No. 10 and may contain potassium hydroxide, and the 150 mg capsules also contain potassium hydroxide. Brands listed are trademarks of their respective owners.

Manufactured In Israel By: **Teva Pharmaceutical Ind. Ltd.**, Kfar Saba, 4410202, Israel

Manufactured For: **Teva Pharmaceuticals**, Parsippany, NJ 07054

This Medication Guide has been approved by the U.S. Food and Drug Administration. Rev. I 9/2022

Package/Label Display Panel

NDC 0093-7384-56

Venlafaxine Hydrochloride Extended-release Capsules, USP

37.5 mg*

SEALED FOR YOUR PROTECTION

PHARMACIST: Dispense the accompanying Medication Guide to each patient.

Rx only

30 Capsules

The label is for Venlafaxine Hydrochloride Extended-release Capsules, USP, 37.5 mg*. It features a barcode on the left with the number 0093-7384-56. Below the barcode is the text '323K30098-03' and 'Rev. E 1/2022'. A large orange box at the bottom left is labeled 'Serialization Coding Area'. The main text on the right includes the product name, strength, and 'SEALED FOR YOUR PROTECTION'. It also states 'PHARMACIST: Dispense the accompanying Medication Guide to each patient.' and 'Rx only 30 Capsules'. The Teva logo is at the bottom right. A small box at the top left contains the text 'Print Medication Guides at: www.tevausa.com/medguides' and '* Each capsule contains venlafaxine hydrochloride, USP equivalent to 37.5 mg venlafaxine. Usual Dosage: See package insert for full prescribing information. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Kfar Saba, 4410202, Israel. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054'. The NDC number 0093-7384-56 and GTIN 00300937384564 are also present.

Package/Label Display Panel

NDC 0093-7385-56

Venlafaxine Hydrochloride Extended-release Capsules, USP

75 mg*

SEALED FOR YOUR PROTECTION

PHARMACIST: Dispense the accompanying Medication Guide to each patient.

Rx only

30 Capsules

The label is for Venlafaxine Hydrochloride Extended-release Capsules, USP, 75 mg*. It features a barcode on the left with the number 0093-7385-56. Below the barcode is the text '323K30100-03' and 'Rev. E 1/2022'. A large orange box at the bottom left is labeled 'Serialization Coding Area'. The main text on the right includes the product name, strength, and 'SEALED FOR YOUR PROTECTION'. It also states 'PHARMACIST: Dispense the accompanying Medication Guide to each patient.' and 'Rx only 30 Capsules'. The Teva logo is at the bottom right. A small box at the top left contains the text 'Print Medication Guides at: www.tevausa.com/medguides' and '* Each capsule contains venlafaxine hydrochloride, USP equivalent to 75 mg venlafaxine. Usual Dosage: See package insert for full prescribing information. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure (as required). KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Manufactured in Israel By: Teva Pharmaceutical Ind. Ltd. Kfar Saba, 4410202, Israel. Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054'. The NDC number 0093-7385-56 and GTIN 00300937385561 are also present.

Package/Label Display Panel

NDC 0093-7386-56

Venlafaxine Hydrochloride Extended-release Capsules, USP

150 mg*

SEALED FOR YOUR PROTECTION

PHARMACIST: Dispense the accompanying Medication Guide to each patient.

Rx only

30 Capsules

3

8

0093-7386-56

323K30102-03

Rev. E 1/2022

Serialization Coding Area

Print Medication Guides at:
www.tevausa.com/medguides

* Each capsule contains venlafaxine hydrochloride, USP equivalent to 150 mg venlafaxine.

Usual Dosage: See package insert for full prescribing information.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from light.

Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure (as required).

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured in Israel By:
Teva Pharmaceutical Ind. Ltd.
Kfar Saba 4410202, Israel

Manufactured For:
Teva Pharmaceuticals
 Parsippany, NJ 07054

GTIN 00300937386568

NDC 0093-7386-56

Venlafaxine Hydrochloride Extended-release Capsules, USP

150 mg*

SEALED FOR YOUR PROTECTION

PHARMACIST: Dispense the accompanying Medication Guide to each patient.

Rx only

30 Capsules

teva

VENLAFAXINE HYDROCHLORIDE			
venlafaxine hydrochloride capsule, extended release			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-7384
Route of Administration	ORAL		
Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)		VENLAFAXINE	37.5 mg
Inactive Ingredients			
Ingredient Name		Strength	
FERROSO FERRIC OXIDE (UNII: XM0M87F357)			
DIBUTYL SEBACATE (UNII: 4W5IH7FLNY)			
ETHYLCELLULOSE (7 MPA.S) (UNII: H3UP11403C)			
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)			
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)			
POVIDONE K30 (UNII: U725QWY32X)			
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)			
SHELLAC (UNII: 46N107B71O)			
SUCROSE (UNII: C151H8M554)			
STARCH, CORN (UNII: O8232NY35J)			
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)			
TALC (UNII: 7SEV7J4R1U)			
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)			
D&C YELLOW NO. 10 (UNII: 35S5USQ3G)			
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)			
Product Characteristics			
Color	gray (light-gray) , brown (buff)	Score	no score
Shape	CAPSULE	Size	18mm
Flavor		Imprint Code	93;7384;93;7384
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-7384-56	30 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
2	NDC:0093-7384-98	90 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
3	NDC:0093-7384-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	03/01/2012	
Marketing Information				
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date	
ANDA	ANDA076565	07/01/2010		

VENLAFAXINE HYDROCHLORIDE

venlafaxine hydrochloride capsule, extended release

Product Information				
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-7385	
Route of Administration	ORAL			
Active Ingredient/Active Moiety				
Ingredient Name		Basis of Strength	Strength	
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)		VENLAFAXINE	75 mg	
Inactive Ingredients				
Ingredient Name		Strength		
FERROSO FERRIC OXIDE (UNII: XM0M87F357)				
DIBUTYL SEBACATE (UNII: 4W5IH7FLNY)				
ETHYLCELLULOSE (7 MPA.S) (UNII: H3UP11403C)				
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)				
POLYETHYLENE GLYCOL 400 (UNII: B6978945GQ)				
POVIDONE K30 (UNII: U725QWY32X)				
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)				
SHELLAC (UNII: 46N107B71O)				
SUCROSE (UNII: C151H8M554)				
STARCH, CORN (UNII: O8232NY3SJ)				
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)				
TALC (UNII: 7SEV7J4R1U)				
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)				
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)				
POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)				
Product Characteristics				
Color	brown (buff)	Score	no score	
Shape	CAPSULE	Size	19mm	
Flavor		Imprint Code	93;7385;93;7385	
Contains				
Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-7385-56	30 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
2	NDC:0093-7385-98	90 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
3	NDC:0093-7385-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	03/01/2012	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA076565	07/01/2010	

VENLAFAXINE HYDROCHLORIDE

venlafaxine hydrochloride capsule, extended release

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0093-7386
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)	VENLAFAXINE	150 mg

Inactive Ingredients

Ingredient Name	Strength
FERROSO FERRIC OXIDE (UNII: XM0M87F357)	
DIBUTYL SEBACATE (UNII: 4W5IH7FLNY)	
ETHYLCELLULOSE (7 MPA.S) (UNII: H3UP11403C)	
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)	
POLYETHYLENE GLYCOL 400 (UNII: B6978945GQ)	
POVIDONE K30 (UNII: U725QWY32X)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	
SHELLAC (UNII: 46N107B71O)	
SUCROSE (UNII: C151H8M554)	
STARCH, CORN (UNII: O8232NY35J)	
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)	
TALC (UNII: 7SEV7J4R1U)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
POTASSIUM HYDROXIDE (UNII: WZ H3C48M4T)	

Product Characteristics

Color	orange (light-orange)	Score	no score
Shape	CAPSULE	Size	23mm
Flavor		Imprint Code	93;7386;93;7386
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0093-7386-56	30 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
2	NDC:0093-7386-98	90 in 1 BOTTLE; Type 0: Not a Combination Product	07/01/2010	
3	NDC:0093-7386-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	03/01/2012	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA076565	07/01/2010	

Labeler - Teva Pharmaceuticals USA, Inc. (001627975)